The purpose of this protocol is to make Stanate (TM) [stannsoporfin, tin-mesoporphyrin]
available to infants who meet the following criteria:
1. the infant has a very high level of bilirubin without an adequate clinical response to
phototherapy;
2. the infant requires an exchange transfusion; and
3. the family refuses to allow the administration of blood products, particularly on
religious grounds, such as within the Jehovah's Witness community.
Details
Lead Sponsor:
InfaCare Pharmaceuticals Corporation InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company